Biotechnology & Medical Research

Page 1

OncoSec Medical announces $13.6 mln registered direct offering

9:42am EDT

OncoSec Medical Inc:Has agreed to sell to such investors an aggregate of 2,469,091 shares of its common stock at a price of $5.50 per share.Gross proceeds of the offering are approximately $13.6 mln.Intends to use proceeds from the offering for general corporate purposes.H.C. Wainwright & Co., LLC acted as the exclusive placement agent for the transaction. Maxim Group LLC and Noble Life Science Partners acted as financial advisors to OncoSec in connection with the transaction.Offering is expected to close on June 5.

Medicinova announces FDA granted orphan drug designation to MN-166

8:00am EDT

Medicinova:Announces FDA granted orphan drug designation to mn-166 (ibudilast) for krabbe disease.Says plan to finalize a protocol and submit it to FDA in order to conduct a clinical trial of mn-166 in krabbe disease.

Ardelyx to raise $77.8 mln in private placement

6:19am EDT

Ardelyx Inc:To raise $77.8 mln in a private placement and announces new product candidate for the treatment of hyperkalemia to begin clinical development in mid-2015.Says initiation of phase 3 program to begin as early as second half 2016.Says Ardelyx announced a new program, rdx022, a non-absorbed polymer, for the treatment of hyperkalemia.Proceeds from the private placement will be used to develop tenapanor and rdx022.

Herantis Pharma Oyj announces results from phase 2 Cis-UCA Dry Eye study

1:01am EDT

Herantis Pharma Oyj:Completed its initial analysis of results of its phase 2 clinical study of Cis-UCA in Dry Eye disease.Cis-UCA did not show statistically significant improvements in two co-primary endpoints for treatment of signs and symptoms of dry eye.Statistically significant efficacy was seen in some secondary endpoints.Cis-UCA was safe and as well tolerated as placebo.

Acorda Therapeutics Inc reaffirms FY 2015 Ampyra revenue guidance - Conference Call

Tuesday, 2 Jun 2015 07:30pm EDT

Acorda Therapeutics Inc:Projects FY 2015 net sales of $405 million to $420 million for Ampyra in MS.

Ligand Pharmaceuticals reaffirms Q2, FY 2015 revenue guidance; raises Q2, FY 2015 EPS guidance

Tuesday, 2 Jun 2015 04:30pm EDT

Ligand Pharmaceuticals:Affirms Q2 2015 expectations for total revenues of between $17.0 million and $17.5 million.Expects Q2 2015 adjusted earnings per diluted share to be between $1.71 and $1.75, compares with previous guidance for adjusted earnings per diluted share to be between $0.37 and $0.40.Affirms expectations for FY 2015 total revenues of between $81.0 million and $83.0 million.Expects FY 2015 adjusted earnings per diluted share to be between $3.45 and $3.50, compares with previous guidance for FY 2015 adjusted earnings per diluted share to be between $2.14 and $2.18.Q2 2015 revenue of $17 million and EPS of $0.40 - Thomson Reuters I/B/E/S.FY 2015 revenue of $82 million and EPS of $2.02 - Thomson Reuters I/B/E/S.

Aptose Biosciences Inc granted orphan drug designation by U.S. FDA for APTO-253

Tuesday, 2 Jun 2015 02:00pm EDT

Aptose Biosciences Inc:Says APTO-253 is currently in phase 1b clinical study in patients with relapsed or refractory hematologic malignancies.Says if APTO-253 is approved to treat AML, the orphan drug designation provides aptose with seven years of marketing exclusivity.

Prothena Corporation PLC presents compelling new data from ongoing phase 1/2 study of neod001 in patients with al amyloidosis

Tuesday, 2 Jun 2015 12:15pm EDT

Prothena Corporation PLC:Says it presents compelling new data from ongoing phase 1/2 study of neod001 in patients with al amyloidosis at 2015 asco annual meeting.Says neod001 continued to be safe and well-tolerated, with no dose limiting toxicities observed.Says expects to present results from expansion portion of the neod001 phase 1/2 study in the fourth quarter of 2015.

Immunomedics says labetuzumab govitecan is active in relapsed metastatic colorectal cancer

Tuesday, 2 Jun 2015 10:24am EDT

Immunomedics:Reports labetuzumab govitecan is active in relapsed metastatic colorectal cancer.Says labetuzumab govitecan was well tolerated by patients.

Markets

  • Sectors
  • U.S.
  • Europe
  • Asia

Sector Summary

Analyst Research

Report Title Price
Provider: Edison Investment Research
$10.00
Provider: Edison Investment Research
$10.00
Provider: Edison Investment Research
$10.00
Provider: Edison Investment Research
$10.00
Provider: Edison Investment Research
$10.00

NYSE and AMEX quotes delayed by at least 20 minutes. NASDAQ delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.